Skip to main content

Table 3 Multivariate Cox proportional hazard analysis

From: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

VariableOverall survivalRelapse-free survival
HR (95% Cl)pHR (95% Cl)p
CA1251 (1–1)0.4951 (1–1)0.98
Stage 0.5 0.98
 Stage I1 1 
 Stage II0.76 (0.14–4.18)0.7551.3 (0.45–3.77)0.627
 Stage III2.21 (0.76–6.41)0.1451.75 (0.79–3.87)0.165
 Stage IV4.89 (1.33–17.9)0.0172.84 (0.96–8.4)0.06
Debulking 0.39 0.9
 Debulking R01 1 
 Debulking R10.62 (0.21–1.84)0.3860.95 (0.4–2.24)0.91
 Debulking R21.35 (0.8–2.27)0.2621.92 (1.21–3.06)0.006
Age1 (0.98–1.03)0.7431.01 (0.99–1.03)0.508
CALR0.96 (0.94–0.99)0.00030.97 (0.96–0.99)0.002
DC-LAMP summary0.8 (0.7–0.91)0.0010.97 (0.94–1.0)0.12
CD8 summary0.99 (0.99–0.99)0.00070.99 (0.99–1)0.13
CD200.23 (0.3–1.54)0.131 (0.33–1.5)0.86
NKp461.08 (0.9–1.3)0.371.11 (0.93–1.35)0.24